{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:56:03Z","timestamp":1793933763278,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium"},{"name":"Janssen Pharmaceutical K.K. Japan"},{"name":"Flanders Innovation & Entrepreneurship (VLAIO), Belgium","award":["IWT 120834"],"award-info":[{"award-number":["IWT 120834"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0415-6","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T18:34:51Z","timestamp":1534962891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: randomized, double-blind, placebo-controlled study"],"prefix":"10.1186","volume":"10","author":[{"given":"Maarten","family":"Timmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Rolf","family":"Streffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Russu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushin","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanaka","family":"Tatikola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Smekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"B\u00f6rjesson-Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Baquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Tesseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Tritsmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Van Nueten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"415_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron M. Alzheimer\u2019s disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387\u201398.","journal-title":"Nat Rev Drug Discov"},{"key":"415_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"415_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735\u201341.","journal-title":"Science"},{"key":"415_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/990114","volume":"402","author":"S Sinha","year":"1999","unstructured":"Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537\u201340.","journal-title":"Nature"},{"key":"415_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/JAD-2010-1367","volume":"20","author":"SD Mulder","year":"2010","unstructured":"Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis. 2010;20:253\u201360.","journal-title":"J Alzheimers Dis"},{"key":"415_CR6","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/archneur.65.8.1102","volume":"65","author":"H Zetterberg","year":"2008","unstructured":"Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008;65:1102\u20137.","journal-title":"Arch Neurol"},{"key":"415_CR7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/archpsyc.64.6.718","volume":"64","author":"Z Zhong","year":"2007","unstructured":"Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007;64:718\u201326.","journal-title":"Arch Gen Psychiatry"},{"key":"415_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3233\/JAD-160829","volume":"56","author":"M Timmers","year":"2017","unstructured":"Timmers M, Barao S, Van Broeck B, Tesseur I, Slemmon J, De Waepenaert K, et al. BACE1 dynamics upon inhibition with a BACE inhibitor and correlation to downstream Alzheimer\u2019s disease markers in elderly healthy participants. J Alzheimers Dis. 2017;56:1437\u201349.","journal-title":"J Alzheimers Dis"},{"key":"415_CR9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.trci.2016.08.001","volume":"2","author":"M Timmers","year":"2016","unstructured":"Timmers M, Van Broeck B, Ramael S, Slemmon J, De Waepenaert K, Russu A, Bogert JM, Stieltjes H, Shaw LM, Engelborghs S, Moechars D, Mercken M, Liu E, Sinha V, Kemp J, Van Nueten L, Tritsmans L, Streffer JR. Profiling the dynamics of CSF and plasma A\u03b2 reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement. 2016;2:202\u201312.","journal-title":"Alzheimers Dement"},{"key":"415_CR10","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1124\/dmd.112.050864","volume":"41","author":"X Liu","year":"2013","unstructured":"Liu X, Wong H, Scearce-Levie K, Watts RJ, Coraggio M, Shin YG, et al. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing. Drug Metab Dispos. 2013;41:1319\u201328.","journal-title":"Drug Metab Dispos"},{"key":"415_CR11","unstructured":"Beal SL, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.2.0 users guides. Ellicott City: Icon Development Solutions; 1989\u20132011."},{"key":"415_CR12","doi-asserted-by":"crossref","unstructured":"Timmerman P, White S, Dougall SM, Kall MA, Smeraglia J, Fjording MS, et al. Tiered approach into practice: scientific validation for chromatography-based assays in early development - a recommendation from the European bioanalysis forum. Bioanalysis 2015;7(18):2387\u201398.","DOI":"10.4155\/bio.15.168"},{"key":"415_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-141986","volume":"45","author":"H Struyfs","year":"2015","unstructured":"Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, et al. Diagnostic accuracy of cerebrospinal fluid amyloid-beta isoforms for early and differential dementia diagnosis. J Alzheimers Dis. 2015;45:813\u201322.","journal-title":"J Alzheimers Dis"},{"key":"415_CR14","unstructured":"Van Broeck B, Borgers M, Meulders G, Hermans B, Dhuyvetter D, Borghys H, Mercken M. Simultaneous evaluation of A\u03b21-37\/38\/40\/42 levels after treatment with secretase inhibitors and modulators using a novel immunoassay [abstract]. Neurodegener Dis. 2013;11(Suppl 1)"},{"key":"415_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2174\/15672050113109990138","volume":"10","author":"S Barao","year":"2013","unstructured":"Barao S, Zhou L, Adamczuk K, Vanhoutvin T, van Leuven F, Demedts D, et al. BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. Curr Alzheimer Res. 2013;10:671\u20138.","journal-title":"Curr Alzheimer Res"},{"key":"415_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/mp.2008.84","volume":"15","author":"P Lewczuk","year":"2010","unstructured":"Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer\u2019s disease: a multicenter study. Mol Psychiatry. 2010;15:138\u201345.","journal-title":"Mol Psychiatry"},{"key":"415_CR17","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282\u20139.","journal-title":"JAMA Neurol"},{"key":"415_CR18","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317:2305\u201316.","journal-title":"JAMA"},{"key":"415_CR19","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1212\/WNL.0000000000002683","volume":"86","author":"PS Insel","year":"2016","unstructured":"Insel PS, Mattsson N, Mackin RS, Scholl M, Nosheny RL, Tosun D, et al. Accelerating rates of cognitive decline and imaging markers associated with beta-amyloid pathology. Neurology. 2016;86:1887\u201396.","journal-title":"Neurology"},{"key":"415_CR20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"415_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"415_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40035-016-0061-5","volume":"5","author":"R Yan","year":"2016","unstructured":"Yan R. Stepping closer to treating Alzheimer\u2019s disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016;5:13.","journal-title":"Transl Neurodegener"},{"key":"415_CR23","doi-asserted-by":"crossref","unstructured":"Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, et al. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2018;378:1691\u2013703.","DOI":"10.1056\/NEJMoa1706441"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0415-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0415-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0415-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T23:01:29Z","timestamp":1604790089000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0415-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0415-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"29 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol and amendments were approved by the appropriate independent ethics committees\/institutional review boards. Written informed consent was obtained from all participants before their participation. All study procedures followed were in accordance with current International Conference on Harmonization guidelines on good clinical practice, applicable regulatory and country-specific requirements, and the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors, except ABH, NA, SE, JMG, MBa, and MBo, report receiving personal fees (employment) from Janssen Research & Development, a Division of Janssen Pharmaceutica N.V., Beerse, Belgium, or Janssen Research & Development, LLC, Raritan, NJ, USA, or Janssen Research and Development LLC, Titusville, NJ, USA, or Janssen Pharmaceutical K.K., Tokyo, Japan, and all own stock\/stock options in the company. JRS is a former employee of Janssen Pharmaceutica NV\u00a0and is currently affiliated with the University of Antwerp with a research advisory role at the Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, and collects no consulting fees and receives no research funding. ABH is employed at Sahlgrenska University Hospital, M\u00f6lndal, Sweden, and has no disclosures to declare. NA is employed at Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Stockholm, Sweden, and has no disclosures to declare. SE is employed at the Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium, and at the Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium, and reports receiving research funding from Janssen Pharmaceutica N.V. and ADx Neurosciences (paid to institution). JMG is an employee of San Carlos Hospital Clinic, Universidad Complutense, Madrid, Spain, and receives salary as chief editor of a scientific journal indexed in Medline and Journal Citation Reports. MBa is an employee of Hospital Universitari i Politecnic La Fe, Valencia, Spain, and has no disclosures to declare. MBo is an employee of Fundaci\u00f3 ACE, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Barcelona, Spain, and consults for Araclon, AstraZeneca, Grifols, Janssen, Kyowa Kirin, Lilly, MSD, Nutricia, Roche, Schwabe, and Servier. MBo has received fees for lectures from Araclon Biotech, Biogen, Grifols, Krka, Nutricia, Roche, and Schwabe, and reports receiving research funding from Araclon Biotech, Bioiberica, Grifols, Krka, Lilly, Merck, Piramal, Nutricia, Roche, Fundaci\u00f3 Bancaria la Caixa, Carlos III Health Institute, the European Commission Horizon 2020 program, European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative, and the European Research Area ERA-NET program.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"85"}}